Gliucovans coated tablets 500 mg/5 mg. №30

Description

GLIUCOVANS TABLETS COMPOSITION
active ingredients:

1 coated tablet 500 mg / 5 mg contains metformin hydrochloride-500 mg, glibenclamide-5 mg

excipients: croscarmellose sodium, povidone, microcrystalline cellulose, magnesium stearate

film shell: opadry 31F22700: lactose monohydrate, hypromellose 15 cP titanium dioxide (E 171) polyethylene glycol quinoline yellow (E 104) iron oxide red (E172) iron oxide yellow (E 172).

GLIUCOVANS TABLETS DOSAGE FORM
Film-coated tablets.

GLIUCOVANS TABLETS MAIN PHYSICAL AND CHEMICAL PROPERTIES:

PHARMACOLOGICAL GROUP
A combination of oral hypoglycemic agents.

ATX code А10В D02.

PHARMACOLOGICAL PROPERTIES

Pharmacological.

Metformin is a biguanide with an antihyperglycemic effect. Reduces plasma glucose levels both on an empty stomach and after meals. Does not stimulate insulin secretion and does not induce a hypoglycemic effect mediated by this mechanism.

Metformin works in three ways:

leads to a decrease in the production of glucose in the liver by inhibiting gluconeogenesis and glycogenolysis
improves insulin sensitivity in muscles, resulting in improved peripheral glucose uptake and utilization
delays the absorption of glucose in the intestine.
Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthetases. Increases the transport capacity of all known types of membrane glucose transporters (GLUT).

Regardless of its effect on blood glucose levels, metformin has a positive effect on lipid metabolism. This effect has been proven with therapeutic dosages in controlled medium- to long-term clinical trials: metformin reduces total cholesterol, low density lipoprotein and triglycerides.

INDICATIONS
Treatment of type 2 diabetes mellitus in adults, to replace previous therapy with two drugs (metformin and glibenclamide) in patients with stable and well-controlled glycemic levels.

CONTRAINDICATIONS
Hypersensitivity to metformin, glibenclamide, other components of the drug or to other sulfonylureas, to sulfonamides
in the case of diabetes mellitus, when insulin treatment is required: type 1 diabetes mellitus (insulin-dependent diabetes mellitus), complete secondary ineffectiveness of glibenclamide therapy in type 2 diabetes mellitus, acidosis, diabetic ketoacidosis, diabetic coma or coma, condition after resection of the pancreas